Press release outlines AACR D3 2026 presentations and ACR-2316 data
Acrivon posted a press release outlining AACR D3 2026 oral and poster presentations highlighting its AP3 platform, centered on WEE1/PKMYT1 inhibitor ACR-2316.
ACR-2316 Phase 1/2 data cited early tumor shrinkage, including partial responses, across AP3-predicted tumor types not previously sensitive to WEE1-class agents.
Conference presentations are scheduled for July 22-23 in Boston, and ACR-2316 is advancing toward dose expansion.
ACRV•
